{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-171157","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.387292+00:00","generated_at":"2026-06-13T20:09:42.172627+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"AlloVir suspends ATM equity program; terminates prospectus supplement with SVB","bullets":["Notified SVB Securities on June 21, 2023 to suspend and terminate the ATM prospectus supplement.","No sales of common stock will be made under the Sales Agreement until a new prospectus supplement or registration statement is filed.","Sales Agreement dated August 6, 2021 remains in full force and effect except for the terminated supplement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-171157","json":"https://secwatch.observer/filing/0001193125-23-171157.json","markdown":"https://secwatch.observer/filing/0001193125-23-171157.md","text":"https://secwatch.observer/filing/0001193125-23-171157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523171157/0001193125-23-171157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523171157/d462085d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:09:42.172627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}